BIIB Related Momentum Movers
-
XenoPort (XNPT) Pops Higher on Biogen (BIIB) Tecfidera Approval
-
Elan Corp. (ELN) Active Following Large Block Trade; Traders Mull Market Chatter
-
Acorda Therapeutics (ACOR) Surges After FAMPYRA Backed in Europe
-
Biogen (BIIB) Rallying 20% in Pre-Market as Results from BG-12 MS Pill Trial Very Strong
-
Biogen (BIIB) Shares at New Session Lows as FDA Ok's Rituxan for Follicular Lymphoma
-
Elan (ELN) Up Following Positive TYSABRI Study Results On Reversing MS Damage
-
Biogen Idec (BIIB) up on reports of an effective drug-cleansing treatment for TYSABRI patients with PML
-
Targeted Genetics (TGEN) Sees Continued Momentum
-
Accentia Biopharmaceuticals (ABPI) Study Shows Positive Data for BiovaxID for Patients Whose Cancer has Relapsed after Chemotherapy
-
ELN Moving on Talk of a Possible Tysabri Update
-
ELN Continue to Move On Speculation of Tysabri Return
Back to BIIB Stock Lookup
